IV Immunoglobulin for Autoimmune Heparin-Induced Thrombocytopenia

Affiliations

¹ Department of Medicine (Division of Hematology and Thromboembolism), Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
² Department of Medicine (Division of Hematology and Thromboembolism), Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; McMaster Centre for Transfusion Research, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: twarken@mcmaster.ca.

Editorial

Shuoyan Ning et al. Chest. 2017 Sep.

. 2017 Sep;152(3):453-455.

doi: 10.1016/j.chest.2017.05.042.

¹ Department of Medicine (Division of Hematology and Thromboembolism), Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
² Department of Medicine (Division of Hematology and Thromboembolism), Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada; McMaster Centre for Transfusion Research, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: twarken@mcmaster.ca.

No abstract available

Comment on

IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia.
Padmanabhan A, Jones CG, Pechauer SM, Curtis BR, Bougie DW, Irani MS, Bryant BJ, Alperin JB, Deloughery TG, Mulvey KP, Dhakal B, Wen R, Wang D, Aster RH. Padmanabhan A, et al. Chest. 2017 Sep;152(3):478-485. doi: 10.1016/j.chest.2017.03.050. Epub 2017 Apr 17. Chest. 2017. PMID: 28427966 Free PMC article.